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A new series of compounds containing a sulfamide moiety as zinc-binding group (ZBG) has been synthesized and tested for
determining inhibitory properties against four human carbonic anhydrase (hCA) isoforms, namely, CAs I, II, IX, and XII. The
X-ray structure of the cytosolic dominant isoform hCA II in complex with the best inhibitor of the series has also been determined
providing further insights into sulfamide binding mechanism and confirming that such zinc-binding group, if opportunely
derivatized, can be usefully exploited for obtaining new potent and selective CAIs. The analysis of the structure also suggests that
for drug design purposes the but-2-yn-1-yloxy moiety tail emerges as a very interesting substituent of the phenylmethylsulfamide
moiety due to its capability to establish strong van derWaals interactions with a hydrophobic cleft on the hCA II surface, delimited
by residues Phe131, Val135, Pro202, and Leu204. Indeed, the complementarity of this tail with the cleft suggests that different
substituents could be used to discriminate between isoforms having clefts with different sizes.
1. Introduction
Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metal-
loenzymes found in prokaryotes and eukaryotes, which
catalyze the reversible hydration of carbon dioxide to
bicarbonate ion and proton (CO
2
+ H
2
O 󴀗󴀰 HCO
3
− + H+)
[1, 2]. In humans 15 different isoforms have been identified so
far, among which 12 are catalytically active (CAs I-IV, VA-VB,
VI-VII, IX, and XII-XIV), whereas the remaining three (CAs
VIII, X, and XI), named as CA-related proteins (CARPs), are
devoid of any catalytic activity [2]. All the catalytically active
isoforms contain in their active site a zinc ion tetrahedrally
coordinated by three conserved histidine residues and awater
molecule/hydroxide ion [1, 2].
Over the past few years, the discovery of the involve-
ment of several CA isoforms in human diseases has greatly
increased the attention on these enzymes in regard to their
consideration as interesting targets for drug design [3].
Indeed, a wealth of derivatives, mainly containing a primary
sulfonamide (RSO
2
NH
2
) [1, 2, 4–6] and its bioisosteres,
such as the sulfamate (ROSO
2
NH
2
) [1, 7, 8] and sulfamide
(RNHSO
2
NH
2
) [1, 2, 9–18] as zinc anchoring groups, have
been investigated as CA inhibitors (CAIs) with some of them
(principally sulfonamides and sulfamates) being explored for
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Figure 1: Chemical formulas of inhibitors 1–16.
the treatment of a variety of disorders such as glaucoma [19–
22], acid-base disequilibria [23], epilepsy [24, 25] neuromus-
cular diseases [26], edema [27], and obesity [28, 29] and
for the management of hypoxic tumors [30]. Acetazolamide
(AAZ) 1 [31], methazolamide (MZA) 2 [31], topiramate
(TPM) 3 [32], ethoxzolamide (EZA) 4 [33], and dichlor-
phenamide (DCP) 5 [31] represent some examples of such
pharmacologically relevant CAIs (Figure 1). However, it is
important to highlight that none of the currently clinically
used CAIs shows selectivity for a specific isozyme [1].
The knowledge of the inhibition profile of CAIs against
all human isoforms and of their detailed binding to the
enzyme (which can be obtained from crystallographic data)
can allow for a better understanding of their mechanism of
action and can provide an efficient molecular basis for the
rational drug design of isozyme-selective compounds [1, 34].
In the last decade a huge number of X-ray structural studies
of CA adducts principally with sulfonamides and sulfamates
have been reported. On the contrary, sulfamide-containing
derivatives have been only poorly investigated as CAIs,
because they were initially supposed not to be particularly
suitable for obtaining potent CA inhibitors, exhibiting just
a moderate-to-weak inhibition potency [35, 36]. However,
many recent studies, predominantly by Supuran’s group, have
supported the idea that sulfamide derivatives can be con-
sidered interesting candidates for obtaining CAIs, showing
such several compounds with relatively high CA affinity [12–
15]. At present, only 5 sulfamide-containing derivatives have
been characterized by means of X-ray crystallography for
their interaction with CAs: the simple sulfamide 6 [9, 16],
the N-hydroxy-sulfamide 7 [10, 18], the sulfamide deriva-
tive of the antiepileptic drug topiramate 8 [11–15, 17], the
boron containing derivative 9 [37], and the nitroimidazole-
sulfamide 10 [38] (Figure 1). Thus we decided to investigate
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Scheme 1: Synthesis of compounds 11–16.
in more detail this class of inhibitors by means of kinetic
and crystallographic studies. In particular, in this paper we
describe the synthesis and the inhibition analysis of a series
of new sulfamides (compounds 11–16) with CA isoforms I, II,
IX, and XII. Furthermore, to better understand at structural
level the molecular features determining the inhibition pro-
files of such compounds, we also report the high-resolution
crystallographic structure of the cytosolic dominant isoform
hCA II in complex with the highest affinity inhibitor (com-
pound 14) in the newly synthesized series.
2. Results and Discussion
2.1. Chemistry. Synthesis of aza-benzylidene derivatives of
sulfamide, like compound 13, from aryl aldehydes and sul-
famide, is reported in the patent literature [39]. Our first
efforts to reproduce a published procedure where ethanol
was used as a solvent resulted in formation of trace amounts
of desired product. After screening of several solvents we
found that the use of glacial acetic acid gave reproducible
results. With the improved procedure, where equimolar
amounts of aryl aldehydes (compounds 20a-b) and sulfamide
(compound 6) were used, monosubstituted aza-benzylidene
derivatives 13 and 15 were isolated in acceptable yields
(Scheme 1). Substituted aryl aldehydes 20a-b were prepared
from 4-hydroxybenzaldehyde 17 and corresponding alcohols
18 or 19 under Mitsunobu reaction conditions [40].
For the synthesis of monobenzyl derivatives of sulfamide,
we chose one-pot two-step procedure [39], where the first
step is the condensation reaction of sulfamide (compound 6)
and aryl aldehydes and the second step is the treatment of
reaction mixture with NaBH
4
, where the reduction of C=N
double bond takes place. Under these conditions utilizing
aldehydes 20a-b, 17, and 21, monosubstituted sulfamides 11,
12, 14, and 16 were obtained (Scheme 1).
2.2. CA Inhibition and Structure-Activity Relationship (SAR).
Sulfamides 11–16 were investigated as inhibitors of four
physiologically relevant CA isoforms, the cytosolic hCAs I
and II, and the transmembrane, tumor-associated hCAs IX
and XII (Table 1). The following SAR can be observed from
the data of Table 1.
(i) hCA I was poorly inhibited by sulfamides 11–16,
which showed a compact behavior of medium-potency,
weak inhibitors, with K
𝐼
s ranging from 1440 to 4050 nM.
Interestingly, the compounds with the bulkier tails, 15 and 16,
were more effective as hCA I inhibitors compared to the
derivatives with the OH, OMe, or alkynyl-ether moieties 11–
14. It may be observed that the standard drug acetazolamide
(AAZ, a clinically used drug) was a more effective hCA I
inhibitor compared to the sulfamides reported here.
(ii) The new sulfamides inhibited the physiologically
dominant cytosolic isoform hCA II with K
𝐼
s ranging from
9.5 to 188 nM. It is interesting to note that derivatives 13 and
14 were effective hCA II inhibitors (comparable to AAZ),
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Table 1: hCAs I, II, IX, and XII inhibition data with sulfamides 11–
16. Acetazolamide (AAZ) has been used as standard drug. Analyses
were performed with a CO2 hydrase, stopped-flow assay [41].
Compounds 𝐾𝐼 (nM)
∗
hCA I hCA II hCA IX hCA XII
11 2180 74.1 40.7 5.8
12 4050 134 60.0 6.6
13 1940 9.8 59.1 8.4
14 1810 9.5 61.7 8.1
15 1650 188 56.3 6.5
16 1440 43.3 62.1 6.6
AAZ 250 12 25 5.7
∗
Mean from 3 different assays, errors in the range of ±10% of the reported
values.
with inhibition constants of 9.5–9.8 nM (Table 1). The two
compounds incorporate the same but-2-yn-1-yloxy-tail and
only differ by the presence of Schiff ’s base (imine) moiety in
compound 13, which is reduced to the secondary amine in
compound 14. It is obvious that this structural modification
has a minimal effect on the hCA II inhibitory properties,
whereas the nature of the tail present in position 4 of the
benzene ring (with respect to the zinc-binding group) has a
crucial role in their binding affinity to the enzyme. Indeed,
the compounds with such smaller moieties (than the but-2-
yn-1-yloxy-one), like 11 and 12, but also those with larger and
bulkier such tails (compounds 15 and 16), were less effective
CAIs compared to compounds 13 and 14 against hCA II.
Indeed, compounds 11 and 16 were medium-potency hCA
II inhibitors (K
𝐼
s ranging from 43.3 to 74.1 nM) whereas
compounds 12 and 15 were even weaker, with inhibition
constants in the range of 134–188 nM (Table 1). The net
difference of activity between compounds 11 and 12 which
only differ by a CH
3
moiety should be noted. In the case of the
imine-amine pair 15, 16, the imine 15 was 4.3 times a weaker
hCA II inhibitor compared to the amine 16.
(iii) Both transmembrane isoforms, hCA IX and XII,
were effectively inhibited by sulfamides 11–16, with little SAR
evident from data of Table 1. Thus, for hCA IX the inhibition
constants only ranged between 40.7 and 62.1 nM, whereas
against hCA XII they were in the range of 5.8–8.4 nM. Thus
all these sulfamides weremedium-potency hCA IX inhibitors
and were highly effective as hCA XII inhibitors (Table 1).
2.3. Crystallography. To better understand at structural level
the molecular features determining the inhibition profiles of
this new series of compounds against hCAs, we have solved
the crystal structure of the cytosolic dominant isoform hCA
II in complex with its highest affinity inhibitor (compound
14) in the series.
Crystals of hCA II/14 adduct were isomorphous with
those of the native protein [42], allowing for the analysis of
the structure by difference Fourier techniques. Data collec-
tion and refinement statistics are shown in Table 2. Inhibitor
binding did not generate major changes in the structure of
hCA II as proved by the low value of the RMSD calculated by
Table 2: Crystal parameters, data collection, and refinement statis-
tics.
Crystal parameters
Space group P21
𝑎 (A˚) 42.4
𝑏 (A˚) 41.3
𝑐 (A˚) 71.8
𝛾 (∘) 104.3
Number of independent molecules 1
Data collection statistics
Resolution (A˚) 50−1.85
Wavelength (A˚) 1.54178
Temperature (K) 100
𝑅merge (%)
a 3.4 (7.1)
Mean 𝐼/𝜎(𝐼) 35.8 (13.6)
Total reflections 80810
Unique reflections 20026
Redundancy (%) 4.0 (2.5)
Completeness (%) 96.1 (84.8)
Refinement statistics
𝑅factor (%)
b 15.6
𝑅free (%)
b 19.6
RMSD from ideal geometry
Bond lengths (A˚) 0.012
Bond angles (∘) 1.7
Number of protein atoms 2091
Number of water molecules 215
Number of inhibitor atoms (2 molecules) 34
Average B factor (A˚2)
All atoms 12.6
Protein atoms 11.6
Inhibitor 1 atoms 19.9
Inhibitor 2 atoms 27.1
Water molecules 20.6
Ramachandran plot
Residues in the most favored regions (%) 88.6
Residues in additional allowed regions (%) 11.0
Residues in generously allowed regions (%) 0.5
a
𝑅merge = ∑ℎ𝑘𝑙 ∑𝑖 |𝐼𝑖(ℎ𝑘𝑙) − ⟨𝐼(ℎ𝑘𝑙)⟩|/∑ℎ𝑘𝑙 ∑𝑖 𝐼𝑖(ℎ𝑘𝑙), where 𝐼𝑖(ℎ𝑘𝑙) is the
intensity of an observation and ⟨𝐼(ℎ𝑘𝑙)⟩ is the mean value for its unique
reflection; summations are over all reflections.
b
𝑅factor =∑ℎ ||Fo(ℎ)|−|Fc(ℎ)||/ ∑ℎ |Fo(ℎ)|, where Fo and Fc are the observed
and calculated structure-factor amplitudes, respectively. 𝑅free is calculated
in same manner as 𝑅factor, except that it uses 5% of the data omitted from
refinement.
superposing theC𝛼 atoms in the adduct and the noninhibited
enzyme (0.3 A˚). The overall quality of the model was high,
with 88.6% of the non-glycine residues located in the allowed
regions of the Ramachandran plot (Table 2).
The inspection of the electron density maps at various
stages of the crystallographic refinement revealed the binding
of two inhibitormolecules: the first one on the protein surface
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Figure 2: Solvent accessible surface of hCA II in its complex with
14. The two molecules of the inhibitor bound within the active site
cavity and on the protein surface are shown in stick representation.
The hydrophobic cleft defined by residues Phe131, Val135, Pro202,
and Leu204 is highlighted in orange.
and the second in the active site cavity (Figure 2).The binding
of the inhibitor on the protein surface will not be discussed
here, since it occurs far from the active site; thus it is not
correlated with the inhibition properties of the molecule. On
the contrary the binding of the molecule in the active site will
be analyzed in detail since it is clearly associatedwith the high
inhibitory potency of the investigated sulfamide.
As clearly evidenced in Figure 3(a) the electron density
for the molecule bound in the active-site is very well defined
for the phenylmethyl sulfamide moiety and slightly less
defined for the but-2-yn-1-yloxy tail indicating some flexibil-
ity of this region.The compound is anchored to the active site
coordinating the catalytic Zn2+ ion by means of one nitrogen
atom of the sulfamide group (N1) and displacing the zinc
bound water molecule/hydroxide ion (Figure 3(a)), similarly
to what is observed for other sulfamides (compounds 6–
10) and sulfonamides/sulfamates whose crystal structures in
adduct with CAs have been reported [16–18, 34, 37]. The
same nitrogen atom N1 also interacts with Thr199 forming a
hydrogen bond with its side chain, whereas one of sulfamide
oxygen atoms forms a second hydrogen bond with the back-
bone nitrogen atom of the same residue (Figure 3(a)). It is
interesting to note that the single bond N2-C1 adopts a trans-
conformation (dihedral angle S1-N2-C1-C2 of about 175∘),
close to the trans-conformation expected for compound 13,
which contains in the same position a double bond. Thus it
is tempting to speculate that this behavior should be at the
basis of the almost identical affinity that the two molecules
show for hCA II (see Table 1).
The phenyl ring of the inhibitor resides in the middle
of the active site channel, making various van der Waals
interactions with the side chains of Phe131, Leu198, Pro201,
and Thr200 while the but-2-yn-1-yloxy tail lies in a small
hydrophobic cleft on the protein surface, defined by residues
Phe131, Val135, Pro202, and Leu204 (Figure 3(b)). This cleft
has already been identified as an important region in the
recognition of CAIs [1, 43]. In agreement with these data,
this interaction seems to have important consequences on
the inhibitory properties of this series of compounds against
hCA II (see Table 1); indeed, inhibitors containing the but-
2-yn-1-yloxy tail (compounds 13 and 14) are those with
the best inhibitory properties against the enzyme, while
compounds with shorter (compounds 11 and 12) or bulkier
(compounds 15 and 16) tails have less inhibitory potency.
Indeed, compounds with shorter tails probably establish less
extensive interactions with this cleft, while those with bulkier
tails are unable to interact with it.
A so clear correlation between the tail and the inhibition
constants is not observed for the other studied isoforms.
Indeed in the case of hCA IX [44] and hCA XII [45] all
studied compounds, although showing good affinity for the
enzymes, present amuch flat inhibition profile, not correlated
to the size of the tail (see Table 1). Interestingly, in both cases
the aforementioned hydrophobic cleft is larger (Figures 3(c)
and 3(d)) and probably does not interact opportunely with
the tail and does not allow a good discrimination.
A different situation is observed in the case of hCA I for
which much higher inhibition constants are observed. The
structural superposition of hCA II/14 complex with hCA I
[46] (Figure 3(f)) can give a reasonable explanation of these
data. Indeed, most of the residues involved in the interaction
of the inhibitor with hCA II are conserved also in the isoform
I. However, the substitution of Thr200 with His200 in hCA I
plays an important role in destabilizing the enzyme-inhibitor
interaction since this residue is much more bulky and makes
the active site narrower (Figures 3(e) and 3(f)).Therefore only
an important structural rearrangement of the enzyme active
site could allow the binding of the inhibitor, determining the
very low affinity toward hCA I, as previously observed for
other hCA I/inhibitor complexes [47].
As mentioned above very few papers describing sulfa-
mide-containing derivatives crystallized with hCA II have
been reported [16–18, 37, 38]. In these adducts a very
weak additional H-bond interaction is observed between the
Thr200OG atom and the second nitrogen atom of the
sulfamide moiety.This weak interaction is absent in our case.
The finding that compound 14 still remains a very good
CA inhibitor despite this absence further confirms that such
interaction does not have a great effect on the stabilization of
the binding.
In conclusion, in this paper we report the X-ray structure
of a new sulfamide inhibitor of CAs in complex with hCA II,
together with an inhibition study of a family of structurally
related compounds for the CA isoforms I, II, IX, and XII.
The data reported here provide further insights into sul-
famide bindingmechanism confirming that this zinc-binding
group could be usefully exploited for obtaining new potent
and selective CAIs. In particular, the but-2-yn-1-yloxy tail
emerges as a very interesting group for this purpose due to
its capability to establish strong van der Waals interactions
with a hydrophobic cleft on the hCA II surface delimited
by residues Phe131, Val135, Pro202, and Leu204. Indeed,
the complementarity of the tail with the cleft suggests that
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Figure 3: (a) Active site region of the hCA II/14 complex. The inhibitor is shown in association with a 𝜎A-weighted |2Fo – Fc|map (at 1.0𝜎).
Hydrogen bonds, van der Waals interactions (distance of <4.0 A˚), and the active site Zn2+-ion coordination are also shown. (b, c, d, and e)
Solvent accessible surface of hCAs II, IX, XII, and I: the hydrophobic cleft defined by residues 131, 135, 202, and 204 is highlighted in orange
(hCA II), blue (hCA IX), green (hCA XII), and magenta (hCA I). For hCA I His200 is also showed in magenta. (f) Structural superposition
of the hCA I (magenta) and hCA II (green) active sites. The inhibitor 14 is shown as bound in its complex with hCA II.
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different substituents could be used to discriminate between
isoforms having cleft with different sizes.
3. Materials and Methods
3.1. Chemistry. Reagents and startingmaterialswere obtained
from commercial sources and used as received. Compound
19 was synthesized according to literature procedure [48].
The solvents were purified and dried by standard procedures
prior to use; petroleum ether (PE) of boiling range 40–
60∘C was used. Flash chromatography was carried out using
Merck silica gel (230–400mesh).Thin-layer chromatography
was performed on silica gel; spots were visualized with UV
light (254 and 365 nm). Melting points were determined on
an OptiMelt automated melting point system. NMR spectra
were recorded on Varian Mercury (400MHz) spectrometer
with chemical shifts values (𝛿) in ppm relative to TMS
using the residual DMSO-𝑑
6
signal as an internal standard.
Elemental analyses were performed on a Carlo Erba CHNS-
O EA-1108 apparatus.
3.1.1. General Procedure for the Synthesis of 4-Alkoxy Sub-
stituted Benzaldehydes. To a mixture of 4-hydroxybenzalde-
hyde (17) (15.58mmol), PPh
3
(16.22mmol), and correspond-
ing alcohol under argon atmosphere dry DCM (100mL)
and dry THF (100mL) were added. To this mixture at
0∘C diisopropyl azodicarboxylate (DIAD) (15.76mmol) was
slowly added and reaction mixture was stirred at room
temperature for 21 h. H
2
O (75mL) and brine (15mL) were
added and themixturewas extractedwithDCM(3× 100mL).
Organic layers were combined, dried over Na
2
SO
4
, and
solvent was evaporated. The crude product was purified by
column chromatography on silica gel.
3.1.2. 4-(But-2-yn-1-yloxy)benzaldehyde (20a). Compound
20a was obtained from 4-hydroxybenzaldehyde (17) (1.90 g,
15.58mmol), PPh
3
(4.27 g, 16.27mmol), but-2-yn-1-ol (18)
(0.87mL, 11.54mmol), and DIAD (3.13mL, 15.82mmol).
The crude product was purified by column chromatography
(toluene) and crystallized from EtOH to yield 20a (1.55 g,
77%) as white solid. Mp 66–68∘C.
1HNMR (400MHz,DMSO-𝑑
6
) 𝛿: 1.84 (t, 3H, 𝐽= 2.3Hz),
4.88 (q, 2H, 𝐽= 2.3Hz), 7.13–7.17 (m, 2H), 7.86–7.90 (m, 2H),
9.88 (s, 1H).
13C NMR (100MHz, DMSO-𝑑
6
) 𝛿: 3.1, 56.3, 74.1, 84.2,
115.2, 130.0, 131.7, 162.3, 191.3.
Anal. Calcd. for C
11
H
10
O
2
(174.20): C, 75.84; H, 5.79.
Found: C, 75.60; H, 5.81.
3.1.3. 4-[(2-Methylquinolin-4-yl)methoxy]benzaldehyde (20b).
Compound 20bwas obtained from 4-hydroxybenzal-dehyde
(17) (1.90 g, 15.58mmol), PPh
3
(4.27 g, 16.27mmol), (2-
methylquinolin-4-yl)methanol(19) [48] (2.00 g, 11.54
mmol), and DIAD (3.13mL, 15.82mmol). The crude product
was purified by column chromatography (PE/EtOAC 3:1 then
1:1) to yield 20b (2.70 g, 85%) as yellow solid. Mp 98–100∘C.
1H NMR (400MHz, DMSO-𝑑
6
) 𝛿: 2.66 (s, 3H), 5.72 (s,
2H), 7.31–7.36 (m, 2H), 7.55 (s, 1H), 7.58 (t, 1H, 𝐽= 7.7Hz), 7.75
(t, 1H, 𝐽= 7.7Hz), 7.88–7.93 (m, 2H), 7.98 (d, 1H, 𝐽= 8.4Hz),
8.10 (d, 1H, 𝐽= 8.4Hz), 9.90 (s, 1H).
13CNMR (100MHz, DMSO-𝑑
6
) 𝛿: 25.0, 66.6, 115.4, 120.2,
123.7, 123.8, 125.9, 128.9, 129.4, 130.1, 131.9, 141.5, 147.4, 158.6,
163.0, 191.3.
Anal. Calcd. for C
18
H
15
NO
2
(277.32): C, 77.96; H, 5.45; N,
5.05. Found: C, 77.66; H, 5.47; N, 5.03.
3.1.4. General Procedure for the Synthesis Benzylidene Sul-
famides. To sulfamide (6) (3.12mmol) glacial acetic acid
(5mL) followed by the corresponding benzaldehyde (3.12
mmol) was added. Reaction mixture was stirred at 60∘C for
23 h. EtOHwas added and solvent was evaporated in vacuum.
The crude product was purified by column chromatography
on silica gel.
3.1.5. N-([4-(But-2-yn-1-yloxy)phenyl]methylidene)sulfuric
Diamide (13). Compound 13 was obtained from sulfamide
(6) (0.30 g, 3.12mmol) and 4-(but-2-yn-1-yloxy)benzal-
dehyde (20a) (0.54 g, 3.12mmol). The crude product was
purified by column chromatography (PE/EtOAc 2 : 1) and
crystallized from MeCN/H
2
O to yield 13 (0.32 g, 41%) as
white solid. Mp 192–194∘C.
1HNMR (400MHz,DMSO-𝑑
6
) 𝛿: 1.84 (t, 3H, 𝐽= 2.4Hz),
4.88 (q, 2H, 𝐽= 2.4Hz), 7.12–7.17 (m, 2H), 7.29 (s, 2H), 7.93–
7.98 (m, 2H), 8.83 (s, 1H).
13C NMR (100MHz, DMSO-𝑑
6
) 𝛿: 3.2, 56.4, 74.1, 84.3,
115.6, 125.6, 132.5, 162.1, 165.7.
Anal. Calcd. for C
11
H
12
N
2
O
3
S (252.29): C, 52.37; H, 4.79;
N, 11.10. Found: C, 52.03; H, 4.72; N, 11.07.
3.1.6. N-({4-[(2-Methylquinolin-4-yl) methoxy]phenyl}methy-
lidene)sulfuric Diamide (15). Compound 15 was obtained
from sulfamide (6) (0.30 g, 3.12mmol) and 4-[(2-methyl-
quinolin-4-yl) methoxy]benzaldehyde (20b) (0.87 g, 3.12
mmol). The crude product was purified by column chro-
matography (PE/EtOAc 2 : 1 then neat EtOAc) and crystal-
lized from EtOH/H
2
O to yield 15 (0.41 g, 37%) as white solid.
Mp 99–101∘C.
1H NMR (400MHz, DMSO-𝑑
6
) 𝛿: 2.67 (s, 3H), 5.75 (s,
2H), 7.31 (s, 2H), 7.33–7.38 (m, 2H), 7.57 (s, 1H), 7.57–7.63 (m,
1H), 7.73–7.78 (m, 1H), 7.96–8.03 (m, 3H), 8.12 (d, 1H, 𝐽=
8.4Hz), 8.86 (s, 1H).
13CNMR (100MHz, DMSO-𝑑
6
) 𝛿: 25.0, 66.6, 115.8, 120.2,
123.7, 123.8, 125.7, 126.0, 128.9, 129.5, 132.7, 141.6, 147.4, 158.6,
162.8, 165.8.
Anal. Calcd. for C
18
H
17
N
3
O
3
S (355.41): C, 60.83; H, 4.82;
N, 11.82. Found: C, 60.39; H, 4.87; N, 11.71.
3.1.7. General One-Pot Procedure for the Synthesis of Mono-
substituted Sulfamide. To sulfamide (6) (1 eq) glacial acetic
acid followed by the corresponding benzaldehyde (1 eq)
was added. Reaction mixture was stirred at 60∘C for 23 h.
NaBH
4
(10 eq) portionwise was added followed by extra
glacial acetic acid. Reaction mixture was stirred at room
temperature for 18 h before it was quenched with sat. aq.
NH
4
Cl. EtOH was added and solvent was evaporated in
vacuum. H
2
O was added and mixture was extracted with
8 BioMed Research International
EtOAc. Combined organic layerswere dried overNa
2
SO
4
and
purified by column chromatography on silica gel.
3.1.8. N-(4-Hydroxybenzyl)sulfuric Diamide (11). Compound
11 was obtained from sulfamide (6) (0.30 g, 3.12mmol),
4-hydroxybenzaldehyde (17) (0.38 g, 3.12mmol) in AcOH
(5mL), and NaBH
4
(1.18 g, 31.2mmol) with extra AcOH
(15mL). Reaction mixture was quenched with sat. aq. NH
4
Cl
(15mL), dilutedwithH
2
O(40mL), and extractedwith EtOAc
(3 × 30mL). The crude product was purified by column
chromatography (PE/EtOAc 1 : 1) to yield 11 (0.10 g, 15%) as
white solid. Mp 140–142∘C.
1H NMR (400MHz, DMSO-𝑑
6
) 𝛿: 3.94 (d, 2H, 𝐽=
6.5Hz), 6.55 (s, 2H), 6.67–6.72 (m, 2H), 6.84 (t, 1H, 𝐽=
6.5Hz), 7.10–7.15 (m, 2H), 9.28 (s, 1H).
13CNMR (100MHz, DMSO-𝑑
6
) 𝛿: 45.8, 114.9, 128.7, 129.0,
156.4.
Anal. Calcd. for C
7
H
10
N
2
O
3
S (202.23): C, 41.57; H, 4.98;
N, 13.85. Found: C, 41.02; H, 5.07; N, 13.67.
3.1.9. N-(4-Methoxybenzyl)sulfuricDiamide (12). Compound
12 was obtained from sulfamide (6) (0.30 g, 3.12mmol), 4-
methoxybenzaldehyde (21) (0.38mL, 3.12mmol) in AcOH
(5mL), and NaBH
4
(1.18 g, 31.2mmol) with extra AcOH
(15mL). Reaction mixture was quenched with sat. aq. NH
4
Cl
(3mL), diluted with H
2
O (50mL), and extracted with
EtOAc (3 × 30mL). The crude product was purified by col-
umn chromatography (PE/EtOAc 2 : 1) and crystallized from
EtOH/H
2
O to yield 12 (0.27 g, 40%) as white solid. Mp 118–
120∘C.
1H NMR (400MHz, DMSO-𝑑
6
) 𝛿: 3.73 (s, 3H), 4.00 (d,
2H, 𝐽= 6.5Hz), 6.88 (s, 2H), 6.85–6.90 (m, 2H), 6.93 (t, 1H,
𝐽= 6.5Hz), 7.23–7.28 (m, 2H).
13C NMR (100MHz, DMSO-𝑑
6
) 𝛿: 45.6, 55.1, 113.6, 129.0,
130.5, 158.3.
Anal. Calcd. for C
8
H
12
N
2
O
3
S (216.26): C, 44.43; H, 5.59;
N, 12.95. Found: C, 44.54; H, 5.52; N, 12.81.
3.1.10. N-[4-(But-2-yn-1-yloxy)benzyl]sulfuric Diamide (14).
Compound 14 was obtained from sulfamide (6) (0.26 g,
2.67mmol), 4-(but-2-yn-1-yloxy)benzaldehyde (20a) (0.47 g,
2.67mmol) in AcOH (5mL), and NaBH
4
(1.01 g, 26.7mmol)
with extra AcOH (15mL). Reaction mixture was quenched
with sat. aq. NH
4
Cl (15mL), diluted with H
2
O (40mL), and
extracted with EtOAc (3 × 30 mL). The crude product was
purified by column chromatography (PE/EtOAc 2 : 1 then 1 : 1)
and crystallized from DCM to yield 14 (0.04 g, 9%) as white
solid. Mp 93–95∘C.
1HNMR (400MHz, DMSO-𝑑
6
) 𝛿: 1.82 (t, 3H, 𝐽= 2.3Hz),
4.00 (d, 2H, 𝐽= 6.3Hz), 4.71 (q, 2H, 𝐽= 2.3Hz), 6.59 (s, 2H),
6.88–6.97 (m, 3H), 7.23–7.28 (m, 2H).
13C NMR (100MHz, DMSO-𝑑
6
) 𝛿: 3.1, 45.6, 55.8, 74.8,
83.4, 114.4, 128.9, 131.1, 156.4.
Anal. Calcd. for C
11
H
14
N
2
O
3
S (254.31): C, 51.95; H, 5.55;
N, 11.02. Found: C, 51.82; H, 5.56; N, 10.97.
3.1.11. N-{4-[(2-Methylquinolin-4-yl)methoxy]benzyl}sulfuric
Diamide (16). Compound 16 was obtained from sulfamide
(6) (0.17 g, 1.80mmol), 4-[(2-methylquinolin-4-yl) methoxy]
benzaldehyde (20b) (0.50 g, 1.80mmol) in AcOH (5mL),
and NaBH
4
(0.68 g, 18.0mmol) with extra AcOH (15mL).
Reaction mixture was quenched with sat. aq. NH
4
Cl (10mL),
diluted with H
2
O (40mL), and extracted with EtOAc (3
× 30mL). The crude product was purified by column
chromatography (PE/EtOAc 1 : 2) to yield 16 (0.14 g, 21%)
as yellow solid. Mp 180-181∘C.
1H NMR (400MHz, DMSO-𝑑
6
) 𝛿: 2.66 (s, 3H), 4.02 (d,
2H, 𝐽= 6.4Hz), 5.60 (s, 2H), 6.60 (s, 2H), 6.97 (t, 1H, 𝐽=
6.4Hz), 7.07–7.12 (m, 2H), 7.28–7.33 (m, 2H), 7.55 (s, 1H), 7.56–
7.61 (m, 1H), 7.72–7.77 (m, 1H), 7.97 (d, 1H, 𝐽= 8.4Hz), 8.10 (d,
1H, 𝐽= 8.4Hz).
13C NMR (100MHz, DMSO-𝑑
6
) 𝛿: 25.0, 45.6, 66.2, 114.6,
120.1, 123.7, 123.9, 125.9, 128.9, 129.1, 129.4, 131.3, 142.4, 147.4,
157.1, 158.6.
Anal. Calcd. for C
18
H
19
N
3
O
3
S (357.43): C, 60.49; H, 5.36;
N, 11.76. Found: C, 60.37; H, 5.38; N, 11.81.
3.2. CA Inhibition Assays. A stopped-flow CO
2
hydration
assay with an Applied Photophysics instrument was used for
measuring the inhibition of hCAs I, II, IX, and XII by the new
compounds reported here. Phenol red (at a concentration
of 0.2mM) has been used as indicator, working at the
absorbance maximum of 557 nm, with 20mM Hepes (pH
7.4) or 20mM Tris (pH 8.3) as buffers, and 20mM Na
2
SO
4
or NaClO
4
(for maintaining the ionic strength constant).
The initial rates of the CA-catalyzed CO
2
hydration reaction
were followed for a period of 10–100 s [41]. The concen-
trations of substrate (CO
2
) ranged from 1.7 to 17mM for
the determination of the inhibition constants, with at least
six traces of the initial 5–10% of the reaction being used
for determining the initial velocity, for each inhibitor. The
uncatalyzed rates were determined and subtracted from the
total observed rates. Stock solutions of inhibitors (10mM)
were prepared in distilled-deionized water and dilutions
up to 0.01 nM were done with the assay buffer. Enzyme
and inhibitor solutions were preincubated prior to assay
for 15min (at room temperature), in order to allow for the
formation of the E-I complex. The inhibition constants were
obtained by nonlinear least-squares methods using PRISM
3 and the Cheng-Prusoff equation as reported earlier by our
groups. The kinetic parameters for the uninhibited enzymes
were derived from Lineweaver-Burk plots, as reported earlier
[49–51], and represent the mean from at least three different
determinations.
3.3. X-Ray Studies. hCA II/14 complex was obtained by
adding a 5-molar excess of inhibitor to a 10mg/mL protein
solution in 20mM Tris-HCl pH 8, 0.1% DMSO. Crystals of
the complex were obtained using the hanging drop vapor dif-
fusion technique. In particular 2 𝜇L of complex solution and
2 𝜇L of precipitant solution (1.4M Na-Citrate, 100mM Tris-
HCl pH 8.0) were mixed and suspended over a reservoir con-
taining 1mL of precipitant solution at 20∘C. X-ray diffraction
data were collected at 100K, using a copper rotating anode
generator developed by Rigaku and equipped with a Rigaku
Saturn CCDdetector. Prior to cryogenic freezing, the crystals
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were transferred to the precipitant solution with the addi-
tion of 15% (v/v) glycerol. Data were processed using the
HKL2000 package [52]. Diffraction data were indexed in the
P2
1
space group with one molecule in the asymmetric unit.
Unit cell parameters and data reduction statistics are reported
in Table 2. The atomic coordinates of hCA II (PDB entry
1CA2) [42] were used as a starting model for crystallographic
refinement after deletion of non-protein atoms. Structure
refinement (in the 20.0–1.85 A˚ resolution range) was carried
out using CNS [53] and model building was performed with
O [54]. Inhibitor molecules were identified from peaks in
|Fo| – |Fc| maps and gradually built into the model over
several rounds of refinement. Restraints on inhibitor bond
angles and distances were taken from similar structures in
the Cambridge Structural Database [55] whereas standard
restraints were used on protein bond angles and distances
throughout refinement. The correctness of stereochemistry
was finally checked using PROCHECK [56]. Final refinement
statistics are presented in Table 2. The atomic coordinates of
hCA II/14 complex were deposited in the Protein Data Bank,
accession code 4PQ7.
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